Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Myeloma highlights from EHA 2019

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 3740

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Prof Maria-Victoria Mateos speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about stand out studies in multiple myeloma.

Prof Mateos begins by discussing the promising part 1 results of the CASSIOPEIA study looking at the addition of daratumumab to bortezomib/thalidomide/dexamethasone (D-VTd) versus VTd in transplant-eligible newly diagnosed multiple myeloma patients.

She also discusses some of the important messages from the FORTE and GEM-CESAR studies.

Prof Mateos ends by discussing the ELOQUENT-3 study in the relapse setting and also the COLUMBA study.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation